Scalera G, Tarozzi G
Dipartimento di Scienze Biomediche, Università di Modena, Italy.
Peptides. 1998;19(6):991-7. doi: 10.1016/s0196-9781(98)00053-9.
The effects of a long period of relatively high and nearly constant levels of Somatostatin (SRIF) on the control of food ingestion and body weight gain were investigated; weight gain occurs via concurrent modifications of food and fluid intake and in vitro gut motility. Fluid intake was not influenced by SRIF treatment. Food intake, body weight, body weight gain, and gut motility decreased after SRIF treatment, and, in some cases, these effects were dose-dependent. Food intake increased significantly during light phase of SRIF treatment. Thus, SRIF treatment produces facilitation of food intake in the light and inhibition in the dark. The suppression seen in the dark may be the result of a preferential activation of the inhibitory response. The increase of food intake during the light may be explained by a decreased availability of body fats as fuels for metabolism since SRIF inhibits GH release, which is involved is the breakdown of adipose tissue into fuels; lower fats synthesis during nocturnal feeding; or both. Decreased gastrointestinal motility also may explain the lower food intake and decreased body weight gain following SRIF treatment.
研究了长期处于相对较高且几乎恒定水平的生长抑素（SRIF）对食物摄取控制和体重增加的影响；体重增加是通过食物和液体摄入量以及体外肠道运动的同时改变而发生的。液体摄入不受SRIF治疗的影响。SRIF治疗后，食物摄入量、体重、体重增加和肠道运动均下降，在某些情况下，这些影响呈剂量依赖性。在SRIF治疗的光照阶段，食物摄入量显著增加。因此，SRIF治疗在光照下促进食物摄取，在黑暗中抑制食物摄取。在黑暗中观察到的抑制作用可能是抑制性反应优先激活的结果。光照期间食物摄入量的增加可能是由于身体脂肪作为代谢燃料的可用性降低，因为SRIF抑制生长激素释放，而生长激素参与脂肪组织分解为燃料；夜间进食期间脂肪合成较低；或者两者皆有。胃肠道运动的降低也可能解释了SRIF治疗后食物摄入量的降低和体重增加的减少。
